

Nadia Withofs, MD, PhD

Date of birth: April 16, 1976

Affiliations:

¹Division of Nuclear Medicine and Oncological Imaging, Department of Medical Physics, CHU of Liege, Avenue de hôpital 1, 4000 Liege, Belgium.

²GIGA-CRC in vivo imaging, University of Liege, Belgium

Phone number: +32 4 284 43 62

E-mail: nwithofs@chuliege.be

EDUCATION AND TRAINING

2001: M.D., Faculty of Medicine, ULiege, Belgium.

2001: Traineeship in Paediatrics, Sainte-Justine Hospital of the University of Montreal.

2002: Residency in Paediatrics, ULiege

2004: Residency in internal Medicine, ULiege

2008: Residency in Nuclear Medicine, ULiege

2009: Research Scholar in the Pr. Sam S. Gambhir's laboratory in the Molecular Imaging Program at Stanford, USA.

2015: PhD, ULiege. Work entitled "Non-invasive PET imaging of tumor integrin $\alpha_v\beta_3$ expression with [¹⁸F]FPRGD2".

SCIENTIFIC HONORS and AWARDS

2007: Research fellowship of BELNUC

2008: Research fellowship (CHU of Liege); PFIZER Award and Travel grant (Foundation Léon Frédéricq, Liege)

2015: The Award of Excellence for the Best Medical Imaging Article in 2014 by the American Association of Physicist in Medicine

SCIENTIFIC SOCIETIES AND JOURNALS

2016-2018 Board member of the Belgian Society of Nuclear medicine (BELNUC)

2018-2020 General secretary of BELNUC

2019-2023 National deputy for the European Society of Nuclear Medicine (EANM)

2019- : Associate editor of the British Journal of Radiology

2019- : Associate editor of the Journal of the French Society of Nuclear Medicine

2021- : Panelist at the "EANM Focus Meeting 4: Imaging and Therapy in Haematological Tumours"; Seville (Spain) on February 4-6, 2021.

Field OF WORK

PET/CT imaging and radionuclide therapy in oncology, including hematological malignancies (myeloma & lymphoma), prostate cancer and neuro-oncology
[¹⁸F]FPRGD₂ PET/CT imaging of musculoskeletal disorders

ACADEMIC & HOSPITAL APPOINTMENTS

2009- : Nuclear medicine physician (full time) at the CHU of Liege, Belgium

2015- : Principal investigator at the GIGA-CRC in vivo imaging, ULiege

2021- : Associate Professor at ULiege

PUBLICATIONS

N = 42; h-index = 13


PET Imaging of Tumor Neovascularization in a Transgenic Mouse Model Using a Novel [⁶⁴Cu]DOTA-Knottin Peptide. Nielsen C. H, Kimura R, Withofs N, Tran P. T, Miao Z, Cochran J, Cheng Z, Felsher D, Kjær A, Willmann J. K, Gambhir S. S. Cancer Res. 2010 Nov 15; 70(22):9022-30.

[¹⁸F]Fluoride PET/CT for assessing bone involvement in prostate and breast cancer. Withofs N, Grayet B, Tancredi T, Rorive A, Mella C, Giacomelli F, Mievis F, Aerts J, Waltregny D, Jerusalem G, Hustinx R. Nucl Med Commun. 2011 Mar; 32(3): 168-76.

Twist1 suppresses senescence programs and thereby accelerates and maintains mutant Kras-induced lung tumorigenesis. Tran PT, Shroff EH, Burns TF, Thiyagarajan S, Das ST, Zabuawala T, Chen J, Cho YJ, Luong R, Tamayo P, Salih T, Aziz K, Adam SJ, Vicent S, Nielsen CH, Withofs N, Sweet-Cordero A, Gambhir SS, Rudin CM, Felsher DW. PLoS Genet. 2012 May; 8(5):e1002650.

Bone mass of the calvarium. Simoni P, Stulko J, Ben Mustapha S, Schoysman L, Bianchi E, Withofs N, Racaru T, Caers J, Alvarez-Miezentseva V. Skeletal Radiol. 2012 Nov 30. § Skeletal Radiol. 2012 Dec 19.

Preliminary results of [¹⁸F]FPRGD₂ PET/CT imaging of integrin $\alpha_v\beta_3$ levels in patients with locally advanced rectal carcinoma. Nadia Withofs, Philippe Martinive, Irene Scagnol, David Thonon, Fabrice Giacomelli, Frederic Mievis, Philippe Coucke, Didier Cataldo, Sanjiv S Gambhir and Roland Hustinx. J Nucl Med. 2012; 53 (Supplement 1):1703



[¹⁸F]FDG PET/CT for rectal carcinoma radiotherapy treatment planning: comparison of functional volume delineation algorithms and clinical challenges. Withofs N, Bernard C, Van der Rest C, Martinive P, Hatt M, Jodogne S, Visvikis D, Lee JA, Coucke PA, Hustinx R. *J Appl Clin Med Phys.* 2014 Sep 8;15(5):4696.

The role of positron emission tomography-computed tomography and magnetic resonance imaging in diagnosis and follow up of multiple myeloma. Caers J, Withofs N, Hillengass J, Simoni P, Zamagni E, Hustinx R, Beguin Y. *Haematologica.* 2014 Apr;99(4):629-37

[¹⁸F]FPRGD₂ PET/CT Imaging of Integrin $\alpha_v\beta_3$ in Renal Carcinomas: Correlation with Histopathology. Withofs N, Signolle N, Somja J, Lovinfosse P, Nzaramba EM, Mievis F, Giacomelli F, Waltregny D, Cataldo D, Gambhir SS, Hustinx R. *J Nucl Med.* 2015 Mar;56(3):361-4

Imaging myeloma and related monoclonal plasma cell disorders using MRI, low-dose whole-body CT and FDG PET/CT. Withofs N, Nanni C, Simoni P, Fanti S, Beguin Y, Caers J. *Clinical and Translational Imaging.* *Clin Transl Imaging* 3, 95–109 (2015).

[¹⁸F]FPRGD₂ PET/CT imaging of musculoskeletal disorders. Withofs N, Charlier E, Simoni P, Alvarez-Miezentseva V, Mievis F, Giacomelli F, Mella C, Gambhir SS, Malaise O, de Seny D, Malaise M, Hustinx R. *Ann Nucl Med.* 2015 Dec;29(10):839-47

Multimodality imaging assessment of the deleterious role of the intraluminal thrombus on the growth of abdominal aortic aneurysm in a rat model. Nchimi A, Courtois A, El Hachemi M, Touat Z, Drion P, Withofs N, Warnock G, Bahri MA, Dogné JM, Cheramy-Bien JP, Schoysman L, Joskin J, Michel JB, Defraigne JO, Plenevaux A, Sakalihan N. *Eur Radiol.* 2016 Jul;26(7):2378-86

[¹⁸F]FPRGD₂ PET/CT imaging of integrin $\alpha_v\beta_3$ levels in patients with locally advanced rectal carcinoma. Withofs N, Martinive P, Vanderick J, Bletard N, Scagnol I, Mievis F, Giacomelli F, Coucke P, Delvenne P, Cataldo D, Gambhir SS, Hustinx R. *Eur J Nucl Med Mol Imaging.* 2016 Apr;43(4):654-62

Updated ESMO Handbook Cancer Diagnosis and Treatment evaluation. Chapter 5- Nuclear medicine imaging and therapy. Jerusalem G, Withofs N. 2016

Integrin $\alpha_v\beta_3$ and RGD-based radiopharmaceuticals. Withofs N, Hustinx R. *MEDECINE NUCLEAIRE Imagerie Fonctionnelle et Métabolique.* 2016 Feb; 40(1): 41–54

Recommendations to stage and assess the response to therapy of lymphomas with [¹⁸F]FDG-PET-CT.

Barrington S, Fosse P, Withofs N, Itti E, Hustinx R, Couturier OF, Meignan M. *MEDECINE NUCLEAIRE Imagerie Fonctionnelle et Métabolique.* 2016 Feb; 40(1): 55–64

A First Report on [¹⁸F]FPRGD₂ PET/CT Imaging in Multiple Myeloma. Withofs N, Cousin F, De Prijck B, Bonnet C, Hustinx R, Gambhir SS, Beguin Y, Caers J. *Contrast Media Mol Imaging.* 2017 Jul 27;2017:6162845

Whole-body computed tomography versus conventional skeletal survey in patients with multiple myeloma: a study of the International Myeloma Working Group. Hillengass J, Mouloupoulos LA, Delorme S, Koutoulidis V, Mosebach J, Hielscher T, Drake M, Rajkumar SV, Oestergaard B, Abildgaard N, Hinge M, Plesner T, Suehara Y, Matsue K, Withofs N, Caers J, Waage A, Goldschmidt H, Dimopoulos MA, Lentzsch S, Durie B, Terpos E. *Blood Cancer J.* 2017 Aug 25;7(8):e599

Molecular mechanisms, current management and next generation therapy in myeloma bone disease. Heusschen R, Muller J, Duray E, Withofs N, Bolomsky A, Baron F, Beguin Y, Menu E, Ludwig H, Caers J. *Leuk Lymphoma.* 2018 Jan;59(1):14-28

Dual-tracer PET/CT scan after injection of combined [¹⁸F]NaF and [¹⁸F]FDG outperforms MRI in the detection of myeloma lesions. Withofs N, Beguin Y, Cousin F, Tancredi T, Simoni P, Alvarez-Miezentseva V, De Prijck B, Hafraoui K, Bonnet C, Baron F, Hustinx R, Caers J. *Hematol Oncol.* 2019 Apr;37(2):193-201.

Interobserver agreement of [⁶⁸Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer. Derwael C, Lavergne O, Lovinfosse P, Nechifor V, Salvé M, Waltregny D, Hustinx R, Withofs N. *EJNMMI Res.* 2020 Feb 28;10(1):15

Toward diagnostic relevance of the $\alpha_v\beta_5$, $\alpha_v\beta_3$, and $\alpha_v\beta_6$ integrins in OA: expression within human cartilage and spinal osteophytes. Charlier E, Deroyer C, Neuville S, Plener Z, Malaise O, Ciregia F, Gillet P, Reuter G, Salvé M, Withofs N, Hustinx R, de Seny D, Malaise M G. *Bone Res.* 2020 Sep 30;8:35.

